MedTrace Logo

Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia

NCT04239950 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 316

Last updated 2024-07-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of ethyl icosapentate in Chinese patients with severe hypertriglyceridemia.

Conditions

  • Hypertriglyceridemia

Interventions

DRUG

Placebo

Placebo

DRUG

Ethyl Icosapentate

Ethyl Icosapentate

Sponsors & Collaborators

  • Sumitomo Pharma (Suzhou) Co., Ltd.

    collaborator INDUSTRY

  • Mochida Pharmaceutical Company, Ltd.

    lead INDUSTRY

Principal Investigators

  • Takuya Mori · Mochida Pharmaceutical Company, Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-09
Primary Completion
2023-07-20
Completion
2023-07-20

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04239950 on ClinicalTrials.gov